Veeva Systems (VEE.DE) Stock Analysis & Winston Score

Veeva Systems builds software specifically for life sciences companies — meaning drug makers, biotech firms, and medical device companies. Its main products help these businesses manage their sales teams, run clinical trials, store regulatory documents, and keep track of customer data. Veeva is one of the dominant software providers focused exclusively on the pharmaceutical and biotech industry. Veeva makes money by charging customers annual subscription fees to use its cloud-based software. Most of its revenue comes from North America and Europe, where large pharmaceutical companies are its biggest clients. The company has a strong competitive position because switching costs are high — once a drug company builds its operations around Veeva's software, replacing it is expensive and disruptive. A key growth driver is expanding its data and analytics products, while a key risk is that a small number of very large pharma clients make up a significant portion of revenue, making the business somewhat dependent on those relationships.